Table 1 Clinical characteristics and the number of SNV/Indel by pathologic diagnosis
Diagnosis | Number of patients | Age | M:F | Ann-Arbor stage | Therapeutic status | Number of SNV/Indel | ||||
|---|---|---|---|---|---|---|---|---|---|---|
median (range) | I or II | III or IV | Pre-Tx. (at diagnosis) | Post-Tx. (relapsed/refractory) | Mean | Median | Range | |||
Mature B-cell neoplasms | 243 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Diffuse large B-cell lymphoma, NOS | 154 | 61 (26–86) | 93:61 | 71 | 83 | 125 | 29 | 24.84 | 23 | 11–87 |
 Primary diffuse large B-cell lymphoma of the CNS | 17 | 62 (34–86) | 10:7 | 17 | 0 | 16 | 1 | 31.53 | 30 | 17–51 |
 Primary mediastinal large B-cell lymphoma | 5 | 36 (25–62) | 3:2 | 1 | 4 | 5 | 0 | 31.80 | 32 | 26–41 |
 EBV-positive diffuse large B-cell lymphoma, NOS | 6 | 62 (19–90) | 4:2 | 2 | 4 | 5 | 1 | 17.00 | 18 | 5–28 |
 High-grade B-cell lymphoma | 6 | 50.5 (37–63) | 5:1 | 1 | 5 | 4 | 2 | 20.83 | 21.5 | 15–27 |
 Burkitt lymphoma | 1 | 69 | 0:1 | 0 | 1 | 0 | 1 | 22.00 | 22 |  |
 Plasmablastic lymphoma | 2 | 58 (52–64) | 2:0 | 1 | 1 | 1 | 1 | 19.50 | 19.5 | 17–22 |
 Follicular lymphoma | 29 | 50 (28–79) | 18:11 | 5 | 24 | 27 | 2 | 19.62 | 18 | 8–35 |
 Mantle cell lymphoma | 11 | 63 (47–80) | 8:3 | 2 | 9 | 7 | 4 | 19.09 | 20 | 11–27 |
 Nodal marginal zone lymphoma | 3 | 59 (58–63) | 1:2 | 2 | 1 | 2 | 1 | 23.33 | 16 | 12–42 |
 Extranodal marginal zone lymphoma of MALT | 4 | 55.5 (44–68) | 2:2 | 3 | 1 | 3 | 1 | 19.25 | 20.5 | 13–23 |
 Lymphoplasmacytic lymphoma | 2 | 59.5 (53–66) | 2:0 | 0 | 2 | 0 | 2 | 17.00 | 17 | 14–20 |
 Chronic lymphocytic leukemia/Small lymphocytic lymphoma | 3 | 56 (53–61) | 1:2 | 0 | 3 | 3 | 0 | 15.33 | 16 | 10–20 |
Mature T- and NK-cell neoplasms | 53 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Peripheral T-cell lymphoma, NOS | 10 | 48 (25–71) | 7:3 | 3 | 7 | 5 | 5 | 17.60 | 18 | 11–23 |
 Angioimmunoblastaic T-cell lymphoma | 10 | 66.5 (43–81) | 5:5 | 0 | 10 | 7 | 3 | 18.70 | 19.5 | 10–24 |
 Follicular T-cell lymphoma | 2 | 50 (48–52) | 2:0 | 0 | 2 | 1 | 1 | 14.00 | 14 | 13–15 |
 Nodal peripheral T-cell lymphoma with TFH phenotype | 4 | 68.5 (64–75) | 3:1 | 0 | 4 | 3 | 1 | 14.25 | 14.5 | 13–15 |
 Extranodal NK/T-cell lymphoma, nasal type | 18 | 56 (32–79) | 11:7 | 11 | 7 | 12 | 6 | 17.44 | 17 | 9–25 |
 Anaplastaic large cell lymphoms, ALK-positive | 5 | 35 (20–58) | 4:1 | 1 | 4 | 4 | 1 | 12.20 | 14 | 6–16 |
 Anaplastaic large cell lymphoms, ALK-neative | 4 | 40 (29–56) | 3:1 | 1 | 3 | 4 | 0 | 22.25 | 23 | 15–28 |
Precursor lymphoid neoplasms | 4 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Lymphoblastic leukemia/lymphoma | 4 | 44.5 (34–70) | 3:1 | 1 | 3 | 4 | 0 | 19.00 | 19.5 | 15–22 |
Total | 300 | 58 (19–90) | 187:113 | 122 | 178 | 238 | 62 | 22.68 | 21 | 5–87 |